Holistic Treatment of Obesity: The Importance of Integrating Pharmacotherapy, Dietary Therapy, and Physical Activity for Effective and Sustained Weight Loss
DOI:
https://doi.org/10.12775/QS.2026.73.75186Keywords
obesity; pharmacotherapy; semaglutide; tirzepatide; dietary therapy; physical activity; comprehensive treatment.Abstract
Introduction. Obesity is a chronic, complex, relapsing disease requiring long-term, individualized management. Incretin-based pharmacotherapy has increased the potential for clinically meaningful weight loss, but maintaining outcomes and limiting adverse body-composition changes also require dietary therapy and physical activity.
Aim. To assess integration of pharmacotherapy, dietary therapy, and physical activity in long-term obesity treatment.
Methods. A narrative literature review covering 2020 - 2026 was conducted, primarily including peer-reviewed publications on adult obesity treatment, as well as guidelines, expert statements, systematic reviews, meta-analyses, and randomized trials.
Results. Semaglutide and tirzepatide enable substantial weight loss and improvement in metabolic parameters. Dietary therapy supports adequate nutrient intake during reduced energy consumption, while physical activity, particularly resistance training, may help preserve fat-free mass and improve body composition. Weight regain may occur after pharmacotherapy discontinuation, supporting long-term treatment.
Conclusions. Obesity treatment should combine pharmacotherapy, dietary therapy, physical activity, and long-term lifestyle change. Assessment should include body weight, metabolic status, body composition, patient functioning, and outcome maintenance.
References
1.World Obesity Federation. World Obesity Atlas 2024. World Obesity Federation; 2024 https://data.worldobesity.org/publications/WOF-Obesity-Atlas-v7.pdf
2.Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., Boyling, E., Brown, J., Calam, B., Clarke, C., Crowshoe, L., Divalentino, D., Forhan, M., Freedhoff, Y., Gagner, M., Glazer, S., … Wicklum, S. (2020). Obesity in adults: a clinical practice guideline. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 192(31), E875–E891. https://doi.org/10.1503/cmaj.191707
3.American Diabetes Association Professional Practice Committee for Diabetes*; 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes–2026. Diabetes Care 1 January 2026; 49 (Supplement_1): S166–S182. https://doi.org/10.2337/dc26-S008
4.van Baak, M. A., & Mariman, E. C. M. (2025). Physiology of Weight Regain after Weight Loss: Latest Insights. Current obesity reports, 14(1), 28. https://doi.org/10.1007/s13679-025-00619-x
5. National Institute for Health and Care Excellence. Overweight and obesity management. NICE guideline NG246. Published January 14, 2025. Updated January 8, 2026. Accessed August 8, 2026. https://www.nice.org.uk/guidance/ng246
6.American Diabetes Association Professional Practice Committee for Diabetes*; 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes - 2026. Diabetes Care 1 January 2026; 49 (Supplement_1): S166 -S182.https://doi.org/10.2337/dc26-S00
7.Roomy, M. A., Hussain, K., Behbehani, H. M., Abu-Farha, J., Al-Harris, R., Ambi, A. M., Abdalla, M. A., Al-Mulla, F., Abu-Farha, M., & Abubaker, J. (2024). Therapeutic advances in obesity management: an overview of the therapeutic interventions. Frontiers in endocrinology, 15, 1364503. https://doi.org/10.3389/fendo.2024.1364503
8., A. L. O., Sandsdal, R. M., Jensen, S. B. K., & Torekov, S. S. (2024). Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety. Obesity reviews : an official journal of the International Association for the Study of Obesity, 25(5), e13717. https://doi.org/10.1111/obr.13717
9.Busetto, L., Dicker, D., Frühbeck, G., Halford, J. C. G., Sbraccia, P., Yumuk, V., & Goossens, G. H. (2024). A new framework for the diagnosis, staging and management of obesity in adults. Nature medicine, 30(9), 2395–2399. https://doi.org/10.1038/s41591-024-03095-3
10.Jakicic, J. M., Apovian, C. M., Barr-Anderson, D. J., Courcoulas, A. P., Donnelly, J. E., Ekkekakis, P., Hopkins, M., Lambert, E. V., Napolitano, M. A., & Volpe, S. L. (2024). Physical Activity and Excess Body Weight and Adiposity for Adults. American College of Sports Medicine Consensus Statement. Medicine and science in sports and exercise, 56(10), 2076–2091. https://doi.org/10.1249/MSS.0000000000003520
11.Steenackers, N., Toumazia, J., Deleus, E., Mertens, A., Lannoo, M., Pazmino, S., van Laar, A. D. E., Van der Schueren, B., & Vangoitsenhoven, R. (2025). Pharmacotherapy for obesity: are we ready to select, tailor and combine pharmacotherapy to achieve more ambitious goals?. Frontiers in endocrinology, 16, 1569468. https://doi.org/10.3389/fendo.2025.1569468
12.Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
13.Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England journal of medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
14.Anazco, D., & Acosta, A. (2025). Precision medicine for obesity: current evidence and insights for personalization of obesity pharmacotherapy. International journal of obesity (2005), 49(3), 452–463. https://doi.org/10.1038/s41366-024-01599-z
15.Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., Hartman, M. L., & Retatrutide Phase 2 Obesity Trial Investigators (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. The New England journal of medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
16.Garvey, W. T., Blüher, M., Osorto Contreras, C. K., Davies, M. J., Winning Lehmann, E., Pietiläinen, K. H., Rubino, D., Sbraccia, P., Wadden, T., Zeuthen, N., Wilding, J. P. H., & REDEFINE 1 Study Group (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 393(7), 635–647. https://doi.org/10.1056/NEJMoa2502081
17., D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., Gulati, M., Gupta, A., Horn, D., Kane, R. M., Saluja, J., Sannidhi, D., Stanford, F. C., & Callahan, E. A. (2025). Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring, Md.), 33(8), 1475–1503. https://doi.org/10.1002/oby.24336
18.Sievenpiper, J. L., Ard, J., Blüher, M., Chen, W., Dixon, J. B., Fitch, A., Gigliotti, L., Khunti, K., Lecube, A., Lean, M. E. J., Mittendorfer, B., Pfeiffer, A. F. H., Ryan, D. H., Vilsbøll, T., & Van Gaal, L. F. (2025). Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 - based therapies: An expert consensus statement using a modified Delphi approach. Obesity pillars, 17, 100228. https://doi.org/10.1016/j.obpill.2025.100228
19.Bruna-Mejias, A., Valenzuela-Fuenzalida, J. J., Oyanedel, G., Figueroa-Puig, J., Cabezas-Salgado, J. J., Orellana-Donoso, M., Cifuentes-Suazo, G., & Loro-Ferrer, J. F. (2026). GLP-1RA- and Incretin-Based Therapies Within Lifestyle Interventions for Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis. Nutrients, 18(11), 1781. https://doi.org/10.3390/nu18111781
20.Sawicka-Gutaj, N., Gruszczyński, D., Nijakowski, K., Derwich-Rudowicz, A., Krenz, M., Kumar, A., Lu, P. Y., & Ruchała, M. (2026). GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis. International journal of obesity (2005), 10.1038/s41366-026-02088-1. Advance online publication. https://doi.org/10.1038/s41366-026-02088-1
21.Lane, M. M., Gamage, E., Du, S., Ashtree, D. N., McGuinness, A. J., Gauci, S., Baker, P., Lawrence, M., Rebholz, C. M., Srour, B., Touvier, M., Jacka, F. N., O'Neil, A., Segasby, T., & Marx, W. (2024). Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses. BMJ (Clinical research ed.), 384, e077310. https://doi.org/10.1136/bmj-2023-077310
22.Jayedi, A., Soltani, S., Emadi, A., Zargar, M. S., & Najafi, A. (2024). Aerobic Exercise and Weight Loss in Adults: A Systematic Review and Dose-Response Meta-Analysis. JAMA network open, 7(12), e2452185. https://doi.org/10.1001/jamanetworkopen.2024.52185
23.Lopez, P., Taaffe, D. R., Galvão, D. A., Newton, R. U., Nonemacher, E. R., Wendt, V. M., Bassanesi, R. N., Turella, D. J. P., & Rech, A. (2022). Resistance training effectiveness on body composition and body weight outcomes in individuals with overweight and obesity across the lifespan: A systematic review and meta-analysis. Obesity reviews : an official journal of the International Association for the Study of Obesity, 23(5), e13428. https://doi.org/10.1111/obr.13428
24.Locatelli, J. C., Costa, J. G., Haynes, A., Naylor, L. H., Fegan, P. G., Yeap, B. B., & Green, D. J. (2024). Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?. Diabetes care, 47(10), 1718–1730. https://doi.org/10.2337/dci23-0100
25.Jensen, S. B. K., Blond, M. B., Sandsdal, R. M., Olsen, L. M., Juhl, C. R., Lundgren, J. R., Janus, C., Stallknecht, B. M., Holst, J. J., Madsbad, S., & Torekov, S. S. (2024). Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine, 69, 102475. https://doi.org/10.1016/j.eclinm.2024.102475
26.Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., Wadden, T. A., Wharton, S., Yokote, K., Kushner, R. F., & STEP 1 Study Group (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, obesity & metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Magdalena Maria Iwaszko, Marcelina Skajewska, Julia Stojko, Wojciech Kwieciński , Oliwia Dziewięcka , Wojciech Ziębka , Bartłomiej Markowski , Damian Szymański, Paweł Iwaszko , WIktoria Biegała
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 23
Number of citations: 0
